Stockreport

REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch [Seeking Alpha]

REGENXBIO Inc.  (RGNX) 
Last regenxbio inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com
PDF Curran Simpson, President and CEO, highlighted strong momentum in late-stage gene therapy programs, emphasizing the progress of RGX-202 for Duchenne muscular dystrophy, [Read more]